Fewer cancers.
Better survival.
Equity for all.

Recent changes in the last 30 days:

New regimens

• LYM NHL B-cell Diffuse large - Pola-R-CHP [polatuzumab vedotin, RITUximab, CYCLOPHOSPHamide, DOXOrubicin and prEDNISone]

• LYM NHL NK/T-cell Extra Nodal - mSMILE [dexamethasone, metHOTREXATe, IFOSFamide, pegaspargase, etoposide] [nasal type]

• LYM NHL NK/T-cell Extra Nodal - P-GemOx [pegaspargase, gemcitabine and oxaliplatin]

• PCN MM - denosumab

• PCN MM - lenalidomide maintenance following LenBorDex lite

• PCN MM - LenBorDex [lenalidomide, bortezomib, and dexamethasone] induction

• PCN MM - LenBorDex lite [lenalidomide, bortezomib, and dexamethasone] induction

• UGI GAST AND OES Locally advanced/Metastatic - TFOX [DOCEtaxel, oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid]

• UGI GAST AND OES Locally advanced/Metastatic - TFOX [DOCEtaxel, oxaliplatin, foliNIc acid and fluorouracil] [low dose foliNIc acid]

Updated regimens

No recent updated regimens

Superseded regimens

• CRC Metastatic - mFOLFIRI [irinotecan, foliNIc acid and fluorouracil [bolus and infusion]] and CETUximab [Q2W] [low dose foliNIc acid]

• CRC Metastatic - mFOLFIRI [irinotecan, foliNIc acid and fluorouracil [bolus and infusion]] [high dose foliNIc acid]

• CRC Metastatic - mFOLFIRI [irinotecan, foliNIc acid and fluorouracil [bolus and infusion]] [low dose foliNIc acid]

• CRC Metastatic - mFOLFIRI [irinotecan, foliNIc acid and fluorouracil [bolus and infusion]] and beVACizumab [high dose foliNIc acid]

• CRC Metastatic - mFOLFIRI [irinotecan, foliNIc acid and fluorouracil [bolus and infusion]] and beVACizumab [low dose foliNIc acid]

• CRC Metastatic - mFOLFIRI [irinotecan, foliNIc acid and fluorouracil [bolus and infusion]] and CETUximab [Q2W] [high dose foliNIc acid]

• CRC Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil [bolus and infusion]] and CETUximab [Q2W] [low dose foliNIc acid]

• CRC Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil [bolus and infusion]] [high dose foliNIc acid]

• CRC Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil [bolus and infusion]] [low dose foliNIc acid]

• CRC Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil [bolus and infusion]] and beVACizumab [high dose foliNIc acid]

• CRC Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil [bolus and infusion]] and beVACizumab [low dose foliNIc acid]

• CRC Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil [bolus and infusion]] and CETUximab [Q2W] [high dose foliNIc acid]

• PCN MM - LenBorDex [lenalidomide, bortezomib, and dexamethasone] induction followed by autologous stem cell transplant

• UGI BIL AND GBC Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil [bolus and infusion]] [high dose foliNIc acid]

• UGI BIL AND GBC Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil [bolus and infusion]] [low dose foliNIc acid]

• UGI GAST AND OES Metastatic - mFOLFIRI [irinotecan, foliNIc acid and fluorouracil [bolus and infusion]] [high dose foliNIc acid]

• UGI GAST AND OES Metastatic - mFOLFIRI [irinotecan, foliNIc acid and fluorouracil [bolus and infusion]] [low dose foliNIc acid]

• UGI GAST AND OES Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil [bolus and infusion]] [high dose foliNIc acid]

• UGI GAST AND OES Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil [bolus and infusion]] [high dose foliNIc acid] and nivolumab

• UGI GAST AND OES Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil [bolus and infusion]] [high dose foliNIc acid] and trastuzumab

• UGI GAST AND OES Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil [bolus and infusion]] [low dose foliNIc acid]

• UGI GAST AND OES Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil [bolus and infusion]] [low dose foliNIc acid] and nivolumab

• UGI GAST AND OES Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil [bolus and infusion]] [low dose foliNIc acid] and trastuzumab

• UGI PANC Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil [bolus and infusion]] [high dose foliNIc acid]

• UGI PANC Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil [bolus and infusion]] [low dose foliNIc acid]

Discontinued regimens

• CRC Adjuvant - mRoswell Park [foliNIc acid and fluorouracil] [high dose foliNIc acid]

• CRC Adjuvant - mRoswell Park [foliNIc acid and fluorouracil] [low dose foliNIc acid]

Regimens taken offline

• HSCT Allogeneic conditioning Non–myeloablative - Flu/TBI 2Gy [fludarabine and low dose total body irradiation 2Gy]

• HSCT Allogeneic conditioning Non–myeloablative - Flu/TBI 2Gy [fludarabine and low dose total body irradiation 2Gy]